BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26568452)

  • 1. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.
    Gandin V; Ferrarese A; Dalla Via M; Marzano C; Chilin A; Marzaro G
    Sci Rep; 2015 Nov; 5():16750. PubMed ID: 26568452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
    Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
    Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
    J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases.
    Oguro Y; Miyamoto N; Takagi T; Okada K; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
    Bioorg Med Chem; 2010 Oct; 18(20):7150-63. PubMed ID: 20833551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of
    Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
    ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entry into a new class of protein kinase inhibitors by pseudo ring design.
    Furet P; Caravatti G; Guagnano V; Lang M; Meyer T; Schoepfer J
    Bioorg Med Chem Lett; 2008 Feb; 18(3):897-900. PubMed ID: 18248988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
    Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
    J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
    Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.
    Ravez S; Arsenlis S; Barczyk A; Dupont A; Frédérick R; Hesse S; Kirsch G; Depreux P; Goossens L
    Bioorg Med Chem; 2015 Nov; 23(22):7340-7. PubMed ID: 26526740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors.
    Chikhale R; Thorat S; Choudhary RK; Gadewal N; Khedekar P
    Bioorg Chem; 2018 Apr; 77():84-100. PubMed ID: 29342447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity.
    Li XY; Zhang TJ; Kamara MO; Lu GQ; Xu HL; Wang DP; Meng FH
    Cell Death Dis; 2019 Jul; 10(7):532. PubMed ID: 31296849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.
    Shan Y; Wang C; Zhang L; Wang J; Wang M; Dong Y
    Bioorg Med Chem; 2016 Feb; 24(4):750-8. PubMed ID: 26753815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of N-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor.
    Iikubo K; Kondoh Y; Shimada I; Matsuya T; Mori K; Ueno Y; Okada M
    Chem Pharm Bull (Tokyo); 2018; 66(3):251-262. PubMed ID: 29491259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.
    Abbas SE; Aly EI; Awadallah FM; Mahmoud WR
    Chem Biol Drug Des; 2015 May; 85(5):608-22. PubMed ID: 25318985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.
    Cai J; Li L; Hong KH; Wu X; Chen J; Wang P; Cao M; Zong X; Ji M
    Bioorg Med Chem; 2014 Nov; 22(21):5813-23. PubMed ID: 25270403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    Shallal HM; Russu WA
    Eur J Med Chem; 2011 Jun; 46(6):2043-57. PubMed ID: 21429632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
    Tan H; Liu Y; Gong C; Zhang J; Huang J; Zhang Q
    Eur J Med Chem; 2021 Nov; 223():113670. PubMed ID: 34214842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of new pyrimidine-4-yl-ethanol derivatives as ROS1 kinase inhibitors.
    Abdelazem AZ; Lee SH
    J Enzyme Inhib Med Chem; 2015 Apr; 30(2):290-8. PubMed ID: 24939104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants.
    Wu TS; Lin WH; Tsai HJ; Hsueh CC; Hsu T; Wang PC; Lin HY; Peng YH; Lu CT; Lee LC; Tu CH; Kung FC; Shiao HY; Yeh TK; Song JS; Chang JY; Su YC; Chen LT; Chen CT; Jiaang WT; Wu SY
    J Med Chem; 2019 Apr; 62(8):3940-3957. PubMed ID: 30968693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.